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Abstract 
Evading the anti-tumor immune response is important for the survival and progression 
of cancer. Recently, we identified an unexpected role for nuclear FAK activity in the 
control of tumor Treg levels and immune evasion by regulating chemokine and 
cytokine transcription in cancer cells. We proposed a potentially new purpose for 
FAK kinase inhibitors, which can cause immune-mediated tumor regression. 
 
Commentary 
Unleashing the anti-tumor immune response is proving to be a very exciting 
therapeutic option in the fight against cancer. Recently, we reported a new and 
surprising function for Focal Adhesion Kinase (FAK) in regulating the immuno-
suppressive tumor environment 1. This led us to propose repurposing FAK inhibitors 
as a new class of immuno-modulatory therapy.  
Briefly, we noticed that the ability of FAK-deficient tumor cells (in our case 
Squamous Cell Carcinoma (SCC)s from which fak had been deleted) to grow was 
quite different in mice that had a functional adaptive immune system (the syngeneic 
FVB host) when compared to mice that did not (CD1 nude mice).  It transpired that 
nuclear FAK activity drives selective chemokine and cytokine transcription, resulting 
in dysfunction of cytotoxic CD8 T-cells and elevated intra-tumoral Tregs – together 
causing suppression of the CD8 T-cell anti-tumor immune response (Figure 1). Lying 
at the heart of this immuno-modulatory activity was a FAK-regulated chemokine 
ligand-receptor paracrine signaling axis between SCC cancer cells and tumor 
infiltrating Tregs. What we uncovered was a function for FAK in controlling tumor 
evasion via induction of an immuno-suppressive tumor microenvironment.  
These findings were surprising for a number of reasons:  
Firstly, when FAK is examined by microscopy, it appears to localize predominantly 
to integrin complexes at sites of cell adhesion to extracellular matrix – the so-called 
focal adhesions (FAs). As such, we assumed its role in cancer was most likely 
biological processes controlled by intracellular signaling from FAs, as have been 
documented over the years, eg. adhesion, polarization, migration, invasion and 
survival 2. FAK is upregulated in many cancers 2, and small molecule inhibitors from 
several pharmaceutical companies are in clinical development 3, 4, with some showing 
clinical activity as a single agent 5. What our work suggests is that good responses to 
FAK inhibitors may be via effects on the immune system, possibly in addition to the 
more widely predicted tumor cell autonomous effects on survival, proliferation and 
invasion.   
Secondly, we had not considered that the most profound effects of FAK in cancer 
might come from its activities in the nucleus. In fibroblasts, endothelial cells, and 
muscle cells, low steady-state levels of nuclear FAK have been identified, with 
increased nuclear accumulation occurring in response to cellular stress 6. We found no 
evidence of nuclear FAK in normal skin keratinocytes (although we did not subject 
these to stress), implying that nuclear accumulation of FAK in malignant keratinocyte 
SCCs was associated with the cancerous phenotype. This raises the exciting 
possibility that the immuno-regulatory function of nuclear FAK may be ‘specific’ to 
cancer, providing a window of therapeutic opportunity. While the full extent of 
FAK’s nuclear functions remain to be elucidated, we note that activated 
(phosphorylated on Tyr-397) nuclear FAK has been identified as a prognostic 
indicator of poor clinical outcome in colorectal cancer 7. 
Finally, having discovered that nuclear FAK was driving an immuno-suppressive 
environment, we were further surprised to find that FAK was associated with 
chromatin, and in wider proteomic and contextualized network analysis (using Ccl5 
as the exemplar FAK-regulated promoter), that FAK binds to components of the basal 
transcription machinery and upstream regulators of key sequence-specific 
transcription factors. While the mechanisms that govern specificity require to be 
worked out, we conclude that FAK scaffolds, in a kinase dependent manner, selective 
regulators of chemokine transcription, in turn leading to Treg recruitment and 
immune evasion. 
Our findings raise a number of interesting corollaries:  Since FAK inhibitors are 
broadly well tolerated, and we do not know of any autoimmune side effects, these 
may have direct therapeutic benefit with relatively minimal side effects when the 
tumor cells are immunogenic. Using a FAK inhibitor currently in clinical 
development (clinicaltrials.gov NCT01849744), VS-4718 4, we observed immune-
mediated SCC tumor regression (effectively curing these mice), and this was 
associated with decreased intra-tumoral Tregs and an elevated anti-tumor CD8 T-cell 
response.  
Of course, not all tumors are highly immunogenic, and tumor-associated cytotoxic T 
cells typically have an exhausted phenotype – features that need to be overcome in 
therapeutic approaches.  In pre-clinical murine cancer models, targeting components 
of the immuno-suppressive microenvironment including Tregs (and macrophages) has 
successfully released the brake on anti-tumor immunity, either alone or in 
combination with agents that stimulate T-cell activity 8, 9. In man, targeting the tumor 
immune environment has changed the treatment of melanoma; indeed, a clinical study 
combining agents that target Programmed Death Receptor-1 (PD-1) and Cytotoxic-T-
Lymphocyte-associated Antigen-4 (CTLA-4), reported an impressive 53% of patients 
with an objective response resulting in greater than 80% reduction in tumor burden 10. 
Whilst there is ‘wind in the sails’ of immunotherapy as a potent arsenal in the fight 
against cancer, there is also the realization that modulating immune cell populations 
can result in severe autoimmune side effects, likely due to disrupting important 
homeostatic functions. For example, the impressive response rate of the combination 
of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) in melanoma was 
accompanied by substantial side effects (clinical grade 3-4) in greater than 50% of 
patients 10. Therefore, while significant progress has been made, and is undoubtedly 
hugely exciting, we need to find alternative effective combinations with improved 
tolerability. We propose that FAK inhibitors may represent one new class of better-
tolerated immuno-modulatory agents. These could complement existing 
immunotherapy treatments, such as checkpoint blockade inhibitors, and clinical 
studies testing this hypothesis are planned. 
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Figure legend: 
 
Figure 1. Schematic summary of our current understanding of how FAK 
signaling in SCC cells contributes to evasion of the anti-tumor immune response. 
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